Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells

Kitayama, S.; Zhang, R.; Liu, T.-Y.; Ueda, N.; Iriguchi, S.; Yasui, Y.; Kawai, Y.; Tatsumi, M.; Hirai, N.; Mizoro, Yasutaka; Iwama, T.; Watanabe, A.; Nakanishi, M.; Kuzushima, K.; Uemura, Y.; Kaneko, S.

doi:10.1016/j.stemcr.2016.01.005

Article (Scientific journals)

Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells

Kitayama, S.; Zhang, R.; Liu, T.-Y. et al.

2016 • In Stem Cell Reports, 6 (2), p. 213-227

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/247966

DOI
10.1016/j.stemcr.2016.01.005

PubMed
26862702

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Kitayama et al. - 2016 - Cellular Adjuvant Properties, Direct Cytotoxicity .pdf

Publisher postprint (3.77 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Valpha24 protein, human; Article; Adjuvants, Immunologic; Cell Death; Cell Differentiation; Cell Line; Humans; Induced Pluripotent Stem Cells; Killer Cells, Natural; Receptors, Antigen, T-Cell

Abstract :

[en] Vα24 invariant natural killer T (iNKT) cells are a subset of T lymphocytes implicated in the regulation of broad immune responses. They recognize lipid antigens presented by CD1d on antigen-presenting cells and induce both innate and adaptive immune responses, which enhance effective immunity against cancer. Conversely, reduced iNKT cell numbers and function have been observed in many patients with cancer. To recover these numbers, we reprogrammed human iNKT cells to pluripotency and then re-differentiated them into regenerated iNKT cells in vitro through an IL-7/IL-15-based optimized cytokine combination. The re-differentiated iNKT cells showed proliferation and IFN-γ production in response to α-galactosylceramide, induced dendritic cell maturation and downstream activation of both cytotoxic T lymphocytes and NK cells, and exhibited NKG2D- and DNAM-1-mediated NK cell-like cytotoxicity against cancer cell lines. The immunological features of re-differentiated iNKT cells and their unlimited availability from induced pluripotent stem cells offer a potentially effective immunotherapy against cancer. © 2016 The Authors.

Disciplines :

Life sciences: Multidisciplinary, general & others

Author, co-author :

Kitayama, S. ^✱; Kyoto University > Center for IPS Cell Research and Application > Department of Cell Growth and Differentiation

Zhang, R. ^✱; Aichi Cancer Center Research Institute > Division of Immunology

Liu, T.-Y.; Aichi Cancer Center Research Institute > Division of Immunology

Ueda, N.; Kyoto University > Center for IPS Cell Research and Application > Department of Cell Growth and Differentiation

Iriguchi, S.; Kyoto University > Center for IPS Cell Research and Application > Department of Cell Growth and Differentiation

Yasui, Y.; Kyoto University > Center for IPS Cell Research and Application > Department of Cell Growth and Differentiation

Kawai, Y.; Kyoto University > Center for IPS Cell Research and Application > Department of Cell Growth and Differentiation

Tatsumi, M.; Aichi Cancer Center Research Institute > Division of Immunology

Hirai, N.; Kyoto University > Center for IPS Cell Research and Application > Department of Cell Growth and Differentiation

Mizoro, Yasutaka ; Kyoto University > Center of iPS Research and Application > Sequencing Core Facility

More authors (6 more)

^✱ These authors have contributed equally to this work.

Language :

English

Title :

Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells

Publication date :

February 2016

Journal title :

Stem Cell Reports

eISSN :

2213-6711

Publisher :

Cell Press

Volume :

Issue :

Pages :

213-227

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 03 June 2020

Statistics

Number of views

30 (1 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

S.P. Berzins, M.J. Smyth, and A.G. Baxter Presumed guilty: natural killer T cell defects and human disease Nat. Rev. Immunol. 11 2011 131 142
P.J. Brennan, M. Brigl, and M.B. Brenner Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions Nat. Rev. Immunol. 13 2013 101 117
E.F. Castillo, L.F. Acero, S.W. Stonier, D. Zhou, and K.S. Schluns Thymic and peripheral microenvironments differentially mediate development and maturation of iNKT cells by IL-15 transpresentation Blood 116 2010 2494 2503
V. Cerundolo, J.D. Silk, S.H. Masri, and M. Salio Harnessing invariant NKT cells in vaccination strategies Nat. Rev. Immunol. 9 2009 28 38
C.J. Chan, L. Martinet, S. Gilfillan, F. Souza-Fonseca-Guimaraes, M.T. Chow, L. Town, D.S. Ritchie, M. Colonna, D.M. Andrews, and M.J. Smyth The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions Nat. Immunol. 15 2014 431 438
D.H. Chang, K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, and et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients J. Exp. Med. 201 2005 1503 1517
M.A. Cheever, J.P. Allison, A.S. Ferris, O.J. Finn, B.M. Hastings, T.T. Hecht, I. Mellman, S.A. Prindiville, J.L. Viner, L.M. Weiner, and et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin. Cancer Res. 15 2009 5323 5337
C. De Santo, R. Arscott, S. Booth, I. Karydis, M. Jones, R. Asher, M. Salio, M. Middleton, and V. Cerundolo Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A Nat. Immunol. 11 2010 1039 1046
G. Eberl, J.P. Di Santo, and E. Vivier The brave new world of innate lymphoid cells Nat. Immunol. 16 2015 1 5
D.I. Godfrey, and S.P. Berzins Control points in NKT-cell development Nat. Rev. Immunol. 7 2007 505 518
D.I. Godfrey, S. Stankovic, and A.G. Baxter Raising the NKT cell family Nat. Immunol. 11 2010 197 206
L.E. Gordy, J.S. Bezbradica, A.I. Flyak, C.T. Spencer, A. Dunkle, J. Sun, A.K. Stanic, M.R. Boothby, Y.W. He, Z. Zhao, and et al. IL-15 regulates homeostasis and terminal maturation of NKT cells J. Immunol. 187 2011 6335 6345
C. Hong, H. Lee, Y.K. Park, J. Shin, S. Jung, H. Kim, S. Hong, and S.H. Park Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells Cancer Res. 69 2009 4301 4308
R.J. Johnston, L. Comps-Agrar, J. Hackney, X. Yu, M. Huseni, Y. Yang, S. Park, V. Javinal, H. Chiu, B. Irving, and et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function Cancer Cell 26 2014 923 937
C. Kuylenstierna, N.K. Bjorkstrom, S.K. Andersson, P. Sahlstrom, L. Bosnjak, D. Paquin-Proulx, K.J. Malmberg, H.G. Ljunggren, M. Moll, and J.K. Sandberg NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d Eur. J. Immunol. 41 2011 1913 1923
P. Li, S. Burke, J. Wang, X. Chen, M. Ortiz, S.C. Lee, D. Lu, L. Campos, D. Goulding, B.L. Ng, and et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion Science 329 2010 85 89
T.Y. Liu, Y. Uemura, M. Suzuki, Y. Narita, S. Hirata, H. Ohyama, O. Ishihara, and S. Matsushita Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells Eur. J. Immunol. 38 2008 1012 1023
M.V. Maus, J.A. Fraietta, B.L. Levine, M. Kalos, Y. Zhao, and C.H. June Adoptive immunotherapy for cancer or viruses Annu. Rev. Immunol. 32 2014 189 225
R.M. McEwen-Smith, M. Salio, and V. Cerundolo The Regulatory role of invariant NKT cells in tumor immunity Cancer Immunol. Res. 3 2015 425 435
L.S. Metelitsa, K.I. Weinberg, P.D. Emanuel, and R.C. Seeger Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells Leukemia 17 2003 1068 1077
D. Mittal, M.M. Gubin, R.D. Schreiber, and M.J. Smyth New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape Curr. Opin. Immunol. 27 2014 16 25
J.W. Molling, W. Kolgen, H.J. van der Vliet, M.F. Boomsma, H. Kruizenga, C.H. Smorenburg, B.G. Molenkamp, J.A. Langendijk, C.R. Leemans, B.M. von Blomberg, and et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load Int. J. Cancer 116 2005 87 93
J.W. Molling, J.A. Langius, J.A. Langendijk, C.R. Leemans, H.J. Bontkes, H.J. van der Vliet, B.M. von Blomberg, R.J. Scheper, and A.J. van den Eertwegh Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma J. Clin. Oncol. 25 2007 862 868
S. Motohashi, A. Ishikawa, E. Ishikawa, M. Otsuji, T. Iizasa, H. Hanaoka, N. Shimizu, S. Horiguchi, Y. Okamoto, S. Fujii, and et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer Clin. Cancer Res. 12 2006 6079 6086
S. Motohashi, K. Nagato, N. Kunii, H. Yamamoto, K. Yamasaki, K. Okita, H. Hanaoka, N. Shimizu, M. Suzuki, I. Yoshino, and et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer J. Immunol. 182 2009 2492 2501
G.T. Motz, and G. Coukos Deciphering and reversing tumor immune suppression Immunity 39 2013 61 73
A. Nicol, M. Nieda, Y. Koezuka, S. Porcelli, K. Suzuki, K. Tadokoro, S. Durrant, and T. Juji Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells Immunology 99 2000 229 234
A.J. Nicol, A. Tazbirkova, and M. Nieda Comparison of clinical and immunological effects of intravenous and intradermal administration of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells Clin. Cancer Res. 17 2011 5140 5151
M. Nieda, A. Nicol, Y. Koezuka, A. Kikuchi, N. Lapteva, Y. Tanaka, K. Tokunaga, K. Suzuki, N. Kayagaki, H. Yagita, and et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells Blood 97 2001 2067 2074
K. Nishimura, M. Sano, M. Ohtaka, B. Furuta, Y. Umemura, Y. Nakajima, Y. Ikehara, T. Kobayashi, H. Segawa, S. Takayasu, and et al. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming J. Biol. Chem. 286 2011 4760 4771
T. Nishimura, S. Kaneko, A. Kawana-Tachikawa, Y. Tajima, H. Goto, D. Zhu, K. Nakayama-Hosoya, S. Iriguchi, Y. Uemura, T. Shimizu, and et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation Cell Stem Cell 12 2013 114 126
R. Noy, and J.W. Pollard Tumor-associated macrophages: from mechanisms to therapy Immunity 41 2014 49 61
M.A. Postow, M.K. Callahan, and J.D. Wolchok Immune checkpoint blockade in cancer therapy J. Clin. Oncol. 33 2015 1974 1982
J. Richter, N. Neparidze, L. Zhang, S. Nair, T. Monesmith, R. Sundaram, F. Miesowicz, K.M. Dhodapkar, and M.V. Dhodapkar Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma Blood 121 2013 423 430
M. Salio, J.D. Silk, E.Y. Jones, and V. Cerundolo Biology of CD1- and MR1-restricted T cells Annu. Rev. Immunol. 32 2014 323 366
A. Schietinger, and P.D. Greenberg Tolerance and exhaustion: defining mechanisms of T cell dysfunction Trends Immunol. 35 2014 51 60
R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
D.K. Shah, and J.C. Zuniga-Pflucker An overview of the intrathymic intricacies of T cell development J. Immunol. 192 2014 4017 4023
L. Song, S. Asgharzadeh, J. Salo, K. Engell, H.W. Wu, R. Sposto, T. Ara, A.M. Silverman, Y.A. DeClerck, R.C. Seeger, and et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages J. Clin. Invest. 119 2009 1524 1536
N. Stanietsky, H. Simic, J. Arapovic, A. Toporik, O. Levy, A. Novik, Z. Levine, M. Beiman, L. Dassa, H. Achdout, and et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity Proc. Natl. Acad. Sci. USA 106 2009 17858 17863
T. Takahashi, M. Nieda, Y. Koezuka, A. Nicol, S.A. Porcelli, Y. Ishikawa, K. Tadokoro, H. Hirai, and T. Juji Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells J. Immunol. 164 2000 4458 4464
G. Trinchieri Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat. Rev. Immunol. 3 2003 133 146
T. Uchida, S. Horiguchi, Y. Tanaka, H. Yamamoto, N. Kunii, S. Motohashi, M. Taniguchi, T. Nakayama, and Y. Okamoto Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer Cancer Immunol. Immunother. 57 2008 337 345
Y. Uemura, T.Y. Liu, Y. Narita, M. Suzuki, R. Nakatsuka, T. Araki, M. Matsumoto, L.K. Iwai, N. Hirosawa, Y. Matsuoka, and et al. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells J. Immunol. 183 2009 201 208
A. Veillette, Z. Dong, and S. Latour Consequence of the SLAM-SAP signaling pathway in innate-like and conventional lymphocytes Immunity 27 2007 698 710
R. Vizcardo, K. Masuda, D. Yamada, T. Ikawa, K. Shimizu, S. Fujii, H. Koseki, and H. Kawamoto Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells Cell Stem Cell 12 2013 31 36
H. Watarai, S. Fujii, D. Yamada, A. Rybouchkin, S. Sakata, Y. Nagata, M. Iida-Kobayashi, E. Sekine-Kondo, K. Shimizu, Y. Shozaki, and et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells J. Clin. Invest. 120 2010 2610 2618
K. Yamasaki, S. Horiguchi, M. Kurosaki, N. Kunii, K. Nagato, H. Hanaoka, N. Shimizu, N. Ueno, S. Yamamoto, M. Taniguchi, and et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy Clin. Immunol. 138 2011 255 265
X. Yu, K. Harden, L.C. Gonzalez, M. Francesco, E. Chiang, B. Irving, I. Tom, S. Ivelja, C.J. Refino, H. Clark, and et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells Nat. Immunol. 10 2009 48 57